☰

Richard Aplenc, Ph.D. - Publications

Affiliations: 
2011 University of Pennsylvania, Philadelphia, PA, United States 
Area:
Epidemiology
Tree Info Similar researchers PubMed Report error

287 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Abla O, Ries RE, Triche TJ, Gerbing RB, Hirsch B, Raimondi S, Cooper TM, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, et al. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Advances. PMID 38306602 DOI: 10.1182/bloodadvances.2023010805  0.34
2023 Cooper TM, Alonzo TA, Tasian SK, Kutny MA, Hitzler J, Pollard JA, Aplenc R, Meshinchi S, Kolb EA. Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. Pediatric Blood & Cancer. e30584. PMID 37480164 DOI: 10.1002/pbc.30584  0.349
2022 Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, ... ... Aplenc R, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood. PMID 36351239 DOI: 10.1182/blood.2022017866  0.301
2022 Pommert L, Cooper TM, Gerbing RB, Brodersen L, Loken M, Gamis A, Aplenc R, Alonzo TA, Kolb EA. Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers. 14. PMID 35158884 DOI: 10.3390/cancers14030616  0.317
2022 Andolina JR, Wang YC, Ji L, Freyer DR, Levine JE, Pulsipher MA, Gamis AS, Aplenc R, Roth ME, Harrison L, Cairo MS. Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. Bone Marrow Transplantation. PMID 34992254 DOI: 10.1038/s41409-021-01558-6  0.303
2021 Rosenfeld E, Getz KD, Miller TP, Seif AE, Fisher BT, Burrows E, Ramos MJ, De León DD, Aplenc R, Morales KH, Guevara JP. Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. Pediatric Blood & Cancer. e29467. PMID 34811879 DOI: 10.1002/pbc.29467  0.306
2021 Huang BJ, Smith J, Wang J, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing RB, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, ... ... Aplenc R, et al. CBFB-MYH11 Fusion Transcripts Distinguish Acute Myeloid Leukemias with Distinct Molecular Landscapes and Outcomes. Blood Advances. PMID 34547772 DOI: 10.1182/bloodadvances.2021004965  0.319
2021 Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, Loken M, Brodersen LE, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer. e29313. PMID 34472213 DOI: 10.1002/pbc.29313  0.301
2020 Brodersen LE, Gerbing RB, Pardo ML, Alonzo TA, Paine D, Fritschle W, Hsu FC, Pollard JA, Aplenc R, Kahwash SB, Hirsch B, Ramondi S, Wells D, Kolb EA, Gamis AS, et al. Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances. 4: 5050-5061. PMID 33080007 DOI: 10.1182/bloodadvances.2020002070  0.345
2020 Hoff FW, van Dijk AD, Qiu YH, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo T, Meshinchi S, De Bont E, Bruggeman SW, Kornblau SM, et al. Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study. Blood. PMID 32959058 DOI: 10.1182/Blood.2020005208  0.386
2020 Ding YY, Ramakrishna S, Long AH, Phillips CA, Montiel-Esparza R, Diorio CJ, Bailey LC, Maude SL, Aplenc R, Batra V, Reilly AF, Rheingold SR, Lacayo NJ, Sakamoto KM, Hunger SP. Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic. Pediatric Blood & Cancer. e28427. PMID 32588960 DOI: 10.1002/Pbc.28427  0.308
2020 Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Hashmi S, Parsons S, Wood WA, Steinberg A, Freytes CO, ... ... Aplenc R, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32464284 DOI: 10.1016/J.Bbmt.2020.05.016  0.389
2020 Wang ES, Aplenc R, Chirnomas D, Dugan M, Fazal S, Iyer S, Lin TL, Nand S, Pierce KJ, Shami PJ, Vermette JJ, Abboud CN. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma. 1-9. PMID 32432489 DOI: 10.1080/10428194.2020.1742897  0.327
2020 Cooper TM, Absalon MJ, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard J, Razzouk BI, Aplenc R, Kolb EA. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903306. PMID 32401633 DOI: 10.1200/Jco.19.03306  0.368
2020 Cahen VC, Li Y, Getz KD, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang YV, Miller TP, Gramatges MM, Rabin KR, Fisher BT, Aplenc R, Seif AE. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatric Blood & Cancer. e28315. PMID 32391940 DOI: 10.1002/Pbc.28315  0.378
2020 Getz KD, Sung L, Alonzo TA, Leger KJ, Gerbing RB, Pollard JA, Cooper T, Kolb EA, Gamis AS, Ky B, Aplenc R. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902856. PMID 32343641 DOI: 10.1200/Jco.19.02856  0.423
2020 Aplenc R. Venetoclax for paediatric acute myeloid leukaemia: a step forward. The Lancet. Oncology. PMID 32171068 DOI: 10.1016/S1470-2045(20)30136-4  0.3
2020 Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Khawash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. PMID 32029509 DOI: 10.3324/Haematol.2019.220962  0.467
2020 Zhao X, Li MM, Schubert J, Wu J, Lin F, Wertheim GB, Surrey L, Luo M, Zhong Y, Wu C, Cao K, Aplenc R, Bagatell R, Mosse YP, Olson TS, et al. Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients. Journal of Clinical Oncology. 38: e13666-e13666. DOI: 10.1200/Jco.2020.38.15_Suppl.E13666  0.327
2020 Leger KJ, Absalon M, Demissei BG, Gerbing RB, Alonzo TA, Hirsch BA, Pollard JA, Razzouk BI, Kolb EA, Aplenc R, Ky B, Cooper TM. Change in cardiac function with CPX-351 in relapsed pediatric AML: A Children’s Oncology Group (COG) report from AAML1421. Journal of Clinical Oncology. 38: 10532-10532. DOI: 10.1200/Jco.2020.38.15_Suppl.10532  0.385
2020 Chow EJ, Aggarwal S, Doody DR, Aplenc R, Armenian S, Baker KS, Bhatia S, Blythe N, Colan S, Constine LS, Freyer DR, Kopp LM, Laverdiere C, Leisenring WM, Sasaki N, et al. Dexrazoxane and heart function among long-term childhood cancer survivors: A Children’s Oncology Group study. Journal of Clinical Oncology. 38: 10513-10513. DOI: 10.1200/Jco.2020.38.15_Suppl.10513  0.343
2020 Andolina JR, Ji L, Wang J, Freyer DR, Levine JE, Pulsipher MA, Gamis A, Aplenc R, Harrison L, Cairo MS. Significantly Increased Risk of Grade II-IV Acute Gvhd in Adolescent and Young Adult (AYA) Recipients (ages ≥13 years) Vs Childhood Recipients (ages 2-12 years) with Acute Leukemia Following Matched Unrelated Donor (MUD) Stem Cell Transplantation (SCT): The Children's Oncology Group Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.745  0.4
2020 Myers RM, Fitzgerald JC, DiNofia A, Wray L, Leahy AB, Li Y, Smith LT, Burrows EK, Ramos M, Motley LS, Khan R, Aplenc R, Grupp SA, Maude SL. Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL) Biology of Blood and Marrow Transplantation. 26: S202-S203. DOI: 10.1016/J.Bbmt.2019.12.695  0.359
2019 Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Current Opinion in Pediatrics. PMID 31815781 DOI: 10.1097/Mop.0000000000000855  0.406
2019 Seif AE, Li Y, Monos DS, Heidemann SC, Aplenc R, Barrett DM, Casper JT, Freedman JL, Grupp SA, Margolis DA, Olson TS, Teachey DT, Keever-Taylor CA, Wang Y, Talano JM, et al. Partially CD3-depleted unrelated and haploidentical donor PSCT has favorable GVHD and survival rates in pediatric hematologic malignancy. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31765697 DOI: 10.1016/J.Bbmt.2019.11.022  0.418
2019 Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, et al. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options - A COG and TARGET Pediatric AML Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31719049 DOI: 10.1158/1078-0432.Ccr-19-1800  0.318
2019 Andriescu EC, Coughlin CC, Cheng CE, Prajapati VH, Huang JT, Schmidt BA, Degar BA, Aplenc R, Pillai V, Yan AC, Liang MG. Pediatric leukemia cutis: A case series. Pediatric Dermatology. PMID 31273836 DOI: 10.1111/Pde.13864  0.303
2019 Nagarajan R, Gerbing R, Alonzo T, Johnston DL, Aplenc R, Kolb EA, Meshinchi S, Barakat LP, Sung L. Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group. Cancer Medicine. PMID 31190442 DOI: 10.1002/Cam4.2337  0.341
2019 Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries RE, Hylkema T, Joaquin J, Sarukkai L, Raimondi S, Hirsch BA, Sung L, Aplenc R, Bernstein ID, Gamis AS, Meshinchi S, et al. Functional Properties of KIT Mutations are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31182436 DOI: 10.1158/1078-0432.Ccr-18-1897  0.302
2019 Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer Journal. 9: 51. PMID 31113932 DOI: 10.1038/S41408-019-0211-Y  0.384
2019 Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE, Bagatell R, Adamson PC, Aplenc R. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatric Blood & Cancer. e27747. PMID 30968531 DOI: 10.1002/Pbc.27747  0.329
2019 Winestone LE, Getz KD, Rao P, Li Y, Hall M, Huang YV, Seif AE, Fisher BT, Aplenc R. Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. Leukemia & Lymphoma. 1-9. PMID 30732497 DOI: 10.1080/10428194.2019.1574002  0.394
2019 Bona KO, Li Y, Winestone L, Getz KD, Huang Y, Fisher B, Desai AV, Richardson T, Hall M, Naranjo A, Henderson TO, Aplenc R, Bagatell R. Poverty and survival in targeted immunotherapy clinical trials. Journal of Clinical Oncology. 37: 10034-10034. DOI: 10.1200/Jco.2019.37.15_Suppl.10034  0.388
2019 Cooper TM, Absalon M, Alonzo TA, Gerbing RB, Leger KJ, Hirsch BA, Pollard JA, Razzouk BI, Aplenc R, Kolb EA. AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group. Journal of Clinical Oncology. 37: 10003-10003. DOI: 10.1200/Jco.2019.37.15_Suppl.10003  0.38
2019 Aplenc R, Sung L, Pollard JA, Brodersen L, Loken M, Gerbing RB, Getz KD, Meshinchi S, Woods WG, Kolb EA, Alonzo TA, Gamis AS. Effect of intensification of induction II chemotherapy and liberalization of stem cell donor source on outcome for children with high risk acute myeloid leukemia: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 37: 10002-10002. DOI: 10.1200/Jco.2019.37.15_Suppl.10002  0.421
2019 Getz KD, Li Y, Szymczak JE, Aftandilian C, Arnold SD, Bona KO, Caywood E, Collier AB, Gramatges MMM, Henry M, Lotterman C, Maloney K, Mian A, Mody R, Raetz EA, ... ... Aplenc R, et al. Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia Blood. 134: 379-379. DOI: 10.1182/Blood-2019-131761  0.393
2019 Getz KD, Sung L, Gerbing RB, Alonzo TA, Li Y, Huang YV, Leger KJ, Pollard JA, Cooper TM, Kolb EA, Gamis AS, Aplenc R. Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group Blood. 134: 331-331. DOI: 10.1182/Blood-2019-131227  0.46
2019 Winestone LE, Getz KD, Bona KO, Fisher BT, Gamis AS, Seif AE, Sung L, Wang Y, Alonzo TA, Aplenc R. Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 134: 703-703. DOI: 10.1182/Blood-2019-130978  0.39
2019 Miller TP, Getz KD, Demissei B, Rabin KR, Daves M, Lupo PJ, Scheurer ME, Burrows E, Fisher BT, Grundmeier RW, Lee J, Wilkes JJ, Winestone LE, Gramatges MMJ, Aplenc R. Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN) Blood. 134: 333-333. DOI: 10.1182/Blood-2019-130656  0.434
2019 Elgarten CW, Li Y, Huang YV, Aplenc R, Hemmer MT, Arora M, Spellman SR, Wang T, Jagasia M, MacMillan ML, Pidala J, Fisher BT, Hall M. Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS) Blood. 134: 599-599. DOI: 10.1182/Blood-2019-130466  0.403
2019 Mangum R, Chambers TM, Stevens A, Lynch RC, Burrows E, Miller TP, Getz KD, Aplenc R, Lupo PJ, Gramatges MMJ, Scheurer ME, Rabin KR. Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium Blood. 134: 1304-1304. DOI: 10.1182/Blood-2019-130351  0.416
2019 Pollard JA, Alonzo TA, Brown PA, Gerbing RB, Fox E, Choi JK, Fisher BT, Hirsch BA, Kahwash S, Levine JE, Loken MR, Raimondi SC, Tarlock K, Wood AC, Sung L, ... ... Aplenc R, et al. Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031 Blood. 134: 292-292. DOI: 10.1182/Blood-2019-129557  0.413
2019 van Dijk AD, Ruvolo PP, Hoff FW, Qiu Y, Gamis AS, Aplenc R, Kolb AE, Alonzo TA, Gerbing RB, de Bont ES, Bruggeman SW, Horton TM, Kornblau SM. Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial Blood. 134: 2676-2676. DOI: 10.1182/Blood-2019-128579  0.408
2019 Tarlock K, Pollard JA, Alonzo TA, Gerbing RB, Wang Y, Ries RE, Smith JL, Kolb EA, Gamis AS, Aplenc R, Meshinchi S. Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile Blood. 134: 119-119. DOI: 10.1182/Blood-2019-127569  0.389
2019 Smith JL, Ries RE, Farrar JE, Alonzo TA, Gerbing RB, Leonti AR, Hylkema TA, Gamis AS, Aplenc R, Kolb EA, Nguyen C, Meerzaman D, Triche TJ, Meshinchi S. Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia - a COG and Tpaml Study Blood. 134: 2741-2741. DOI: 10.1182/Blood-2019-127318  0.397
2019 Tarlock K, Eidenschink Brodersen L, Alonzo TA, Wang Y, Gerbing RB, Pardo L, Dai F, Gamis AS, Aplenc R, Pollard JA, Loken MR, Meshinchi S. CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia Blood. 134: 2699-2699. DOI: 10.1182/Blood-2019-127100  0.357
2019 Myers RM, Fitzgerald JC, DiNofia AM, Wray L, Barz Leahy A, Li Y, Smith L, Burrows E, Ramos M, Motley LS, Khan RN, Getz KD, Aplenc R, Grupp S, Maude SL. Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019 Blood. 134: 61-61. DOI: 10.1182/Blood-2019-126724  0.417
2019 Tarlock K, Alonzo TA, Wang Y, Gerbing RB, Ries RE, Hylkema TA, Woods WG, Cooper TM, Gamis AS, Aplenc R, Meshinchi S. Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation Blood. 134: 181-181. DOI: 10.1182/Blood-2019-126273  0.319
2019 Ries RE, Leonti AR, Triche TJ, Gerbing RB, Hirsch BA, Raimondi SC, Smith JL, Cooper TM, Farrar JE, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study Blood. 134: 461-461. DOI: 10.1182/Blood-2019-125943  0.398
2019 Lamble AJ, Eidenschink Brodersen L, Alonzo TA, Wang J, Gerbing RB, Pardo L, Sung L, Tasian SK, Cooper TM, Kolb EA, Aplenc R, Loken MR, Meshinchi S. Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 134: 459-459. DOI: 10.1182/Blood-2019-124587  0.387
2019 Leonti AR, Pardo L, Alonzo TA, Gerbing RB, Eidenschink Brodersen L, Ries RE, Smith JL, Le Q, Aplenc R, Kolb EA, Magnani JL, Fogler WE, Loken MR, Meshinchi S. Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML Blood. 134: 3772-3772. DOI: 10.1182/Blood-2019-124525  0.342
2019 Ding L, Martin AE, Canepa E, Evans E, Aplenc R, Szymczak JE, Joseph G, Winestone LE. Disparities in Barriers and Facilitators of Acute Leukemia Diagnosis in Young Patients Blood. 134: 3415-3415. DOI: 10.1182/Blood-2019-124236  0.362
2019 Yi JS, Chambers T, Getz KD, Miller TP, Burrows E, Daves M, Lupo PJ, Scheurer ME, Aplenc R, Rabin KR, Gramatges MMJ. Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium Blood. 134: 3814-3814. DOI: 10.1182/Blood-2019-123992  0.42
2019 Seif AE, Li Y, Cahen VC, Huang YV, Hall M, Kolb EA, Fisher BT, Aplenc R, Getz KD. Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS) Blood. 134: 3496-3496. DOI: 10.1182/Blood-2019-122887  0.447
2019 Myers RM, Fitzgerald J, Elgarten CW, Getz KD, Li Y, Hogan J, Dinofia A, Burrows EK, Aplenc R, Grupp SA, Laskin B, Maude SL. Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia Biology of Blood and Marrow Transplantation. 25: S168-S169. DOI: 10.1016/J.Bbmt.2018.12.307  0.401
2018 Li Y, Newton JG, Getz KD, Huang YS, Seif AE, Fisher BT, Aplenc R, Winestone LE. Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia. Pediatric Blood & Cancer. e27583. PMID 30585685 DOI: 10.1002/Pbc.27583  0.369
2018 Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Leahy AB, Sack L, Woods WG, Alonzo T, Gamis A, Aplenc R. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800313. PMID 30379624 DOI: 10.1200/Jco.18.00313  0.416
2018 Desai AV, Li Y, Getz K, Seif AE, Fisher B, Huang V, Aplenc R, Bagatell R. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. Pediatric Blood & Cancer. e27372. PMID 30070014 DOI: 10.1002/Pbc.27372  0.376
2018 Elgarten CW, Arnold SD, Li Y, Huang YV, Riches ML, Gerber JS, Aplenc R, Saber W, Fisher BT. Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. Infection Control and Hospital Epidemiology. 1-9. PMID 29734957 DOI: 10.1017/Ice.2018.96  0.351
2018 Getz KD, He C, Li Y, Huang YV, Burstein DS, Rossano J, Aplenc R. Successful merging of data from the United Network for Organ Sharing and the Pediatric Health Information System databases. Pediatric Transplantation. e13168. PMID 29635813 DOI: 10.1111/Petr.13168  0.319
2018 Citrin R, Getz KD, Li Y, Huang YS, Horowitz JP, Seif AE, Fisher BT, Aplenc R. The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. British Journal of Haematology. PMID 29611176 DOI: 10.1111/Bjh.15159  0.36
2018 Fitzgerald JC, Li Y, Fisher BT, Huang YS, Miller TP, Bagatell R, Seif AE, Aplenc R, Thomas NJ. Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia. Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. PMID 29528977 DOI: 10.1097/Pcc.0000000000001525  0.328
2018 Getz KD, Miller TP, Seif AE, Li Y, Huang YV, Fisher BT, Aplenc R. Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. Plos One. 13: e0192529. PMID 29420604 DOI: 10.1371/Journal.Pone.0192529  0.349
2018 Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood. PMID 29305553 DOI: 10.1182/Blood-2017-07-794214  0.341
2018 Getz KD, Sung L, Leger K, Alonzo TA, Gerbing RB, Cooper TM, Kolb E, Gamis AS, Ky B, Aplenc R. Effect of dexrazoxane on left ventricular function and treatment outcomes in patients with acute myeloid leukemia: A Children’s Oncology Group report. Journal of Clinical Oncology. 36: 10501-10501. DOI: 10.1200/Jco.2018.36.15_Suppl.10501  0.399
2018 Winestone LE, Getz KD, Li Y, Burrows E, Scheurer M, Gramatges MM, Wilkes JJ, Miller TP, Seif AE, Grundmeier RW, Rabin KR, Fisher BT, Aplenc R. Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia Blood. 132: 369-369. DOI: 10.1182/Blood-2018-99-120076  0.407
2018 Barz Leahy A, Elgarten CW, Li Y, Huang YV, Fisher BT, Delp D, Aplenc R, Getz KD. Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like? Blood. 132: 4763-4763. DOI: 10.1182/Blood-2018-99-119970  0.391
2018 Barz Leahy A, Helton G, Scholes D, Jurgielewicz A, Reeve BB, Lisa S, Aplenc R, Basch E. Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study Blood. 132: 2290-2290. DOI: 10.1182/Blood-2018-99-119902  0.33
2018 Elgarten CW, Getz KD, Huang YV, Myers RM, Burrows E, Tam VW, Aplenc R, Fisher BT. Assessing Neighborhood Characteristics As Risk Factors for Bloodstream Infection in Children with Acute Leukemia Blood. 132: 833-833. DOI: 10.1182/Blood-2018-99-119499  0.426
2018 Place AE, Blonquist TM, Stieglitz E, Cooper TM, Gore L, Aplenc R, Loh ML, Pauly M, Rau RE, Burke MJ, Etchin J, Look AT, Sulis ML, Silverman LB. Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia Blood. 132: 1405-1405. DOI: 10.1182/Blood-2018-99-116689  0.351
2018 Yi JS, Chambers TS, Getz KD, Scheurer M, Lupo PJ, Burrows E, Daves M, Aplenc R, Rabin KR, Gramatges MM. Comparing the Liver Function of Children with Acute Lymphoblastic Leukemia (ALL) Receiving Standard or High Intensity Treatment during the Interim Maintenance I Phase of Therapy: A Study of 658 Patients Blood. 132: 1383-1383. DOI: 10.1182/Blood-2018-99-115691  0.427
2018 Pardo L, Eidenschink Brodersen L, Lamba JK, Alonzo TA, Wang Y, Paine D, Gamis AS, Kolb EA, Pollard JA, Cooper TM, Aplenc R, Meshinchi S, Loken MR. Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531 Blood. 132: 1490-1490. DOI: 10.1182/Blood-2018-99-115053  0.336
2018 Myers RM, Getz KD, Li Y, Huang YV, Citrin R, Elgarten CW, Laskin BL, Horowitz JP, Fisher BT, Aplenc R. Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data Blood. 132: 830-830. DOI: 10.1182/Blood-2018-99-114883  0.426
2018 Cahen VC, Li Y, Burrows E, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang YV, Fitzgerald JC, Gramatges MM, Rabin KR, Fisher BT, Getz KD, Aplenc R, Seif AE. A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort Blood. 132: 3597-3597. DOI: 10.1182/Blood-2018-99-114235  0.403
2018 Cahen VC, Li Y, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang YV, Gramatges MM, Rabin KR, Fisher BT, Getz KD, Aplenc R, Seif AE. Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort Blood. 132: 624-624. DOI: 10.1182/Blood-2018-99-114228  0.453
2018 Nagarajan R, Alonzo TA, Gerbing RB, Johnston D, Aplenc R, Kolb EA, Meshinchi S, Barakat L, Sung L. Quality of Life in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 132: 4841-4841. DOI: 10.1182/Blood-2018-99-112152  0.416
2018 Hoff FW, Qiu Y, Hu W, Qutub AA, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, de Bont ES, Horton TM, Kornblau SM. Proteomic Landscape of De Novo Pediatric Acute Myeloid Leukemia Blood. 132: 294-294. DOI: 10.1182/Blood-2018-99-110796  0.336
2018 Hoff FW, Hu W, Qiu Y, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Qutub AA, de Bont ES, Bruggeman SW, Kornblau SM, Horton TM. RPPA-Profiling Identifies Patients with Low Phosphorylation Levels of HSF1 at Serine 326 As Potential Candidate for Bortezomib Treatment in Addition to Standard Therapy in Pediatric Acute Myeloid Leukemia Blood. 132: 293-293. DOI: 10.1182/Blood-2018-99-110730  0.365
2017 Szymczak JE, Getz KD, Madding R, Fisher B, Raetz E, Hijiya N, Gramatges MM, Henry M, Mian A, Arnold SD, Aftandilian C, Collier AB, Aplenc R. Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia. Pediatric Blood & Cancer. PMID 29286570 DOI: 10.1002/Pbc.26927  0.352
2017 DiNofia AM, Seif AE, Devidas M, Li Y, Hall M, Huang YV, Cahen V, Hunger SP, Winick NJ, Carroll WL, Fisher BT, Larsen EC, Aplenc R. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. Cancer Medicine. PMID 29274118 DOI: 10.1002/Cam4.1206  0.359
2017 Lim EL, Trinh DL, Ries RE, Wang J, Gerbing RB, Ma Y, Topham J, Hughes M, Pleasance E, Mungall AJ, Moore R, Zhao Y, Aplenc R, Sung L, Kolb EA, et al. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017747451. PMID 29068783 DOI: 10.1200/Jco.2017.74.7451  0.302
2017 Citrin R, Horowitz JP, Reilly AF, Li Y, Huang YS, Getz KD, Seif AE, Fisher BT, Aplenc R. Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. Plos One. 12: e0186960. PMID 29059235 DOI: 10.1371/Journal.Pone.0186960  0.344
2017 Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO, et al. Clinical risks and healthcare utilization of haematopoietic cell transplantation for sickle cell disease in the U.S. using merged databases. Haematologica. PMID 28818869 DOI: 10.3324/Haematol.2017.169581  0.374
2017 Winestone LE, Getz KD, Miller TP, Li Y, Huang YS, Seif AE, Fisher BT, Aplenc R. Complications preceding early deaths in Black and White children with acute myeloid leukemia. Pediatric Blood & Cancer. PMID 28727288 DOI: 10.1002/Pbc.26712  0.338
2017 Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531. Blood. PMID 28674028 DOI: 10.1182/Blood-2017-01-762336  0.354
2017 Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016712513. PMID 28644774 DOI: 10.1200/Jco.2016.71.2513  0.401
2017 Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, ... ... Aplenc R, et al. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Haematologica. PMID 28642300 DOI: 10.3324/Haematol.2017.168815  0.396
2017 Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS. Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 28453910 DOI: 10.1002/Pbc.26612  0.398
2017 Hanley MJ, Mould DR, Taylor TJ, Gupta N, Suryanarayan K, Neuwirth R, Esseltine DL, Horton TM, Aplenc R, Alonzo TA, Lu X, Milton A, Venkatakrishnan K. Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. Journal of Clinical Pharmacology. PMID 28419486 DOI: 10.1002/Jcph.906  0.371
2017 Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. PMID 28411282 DOI: 10.1182/Blood-2017-03-772384  0.429
2017 Miller TP, Li Y, Getz KD, Dudley J, Burrows E, Pennington J, Ibrahimova A, Fisher BT, Bagatell R, Seif AE, Grundmeier R, Aplenc R. Using electronic medical record data to report laboratory adverse events. British Journal of Haematology. PMID 28146330 DOI: 10.1111/Bjh.14538  0.313
2017 Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi S, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S. Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28108543 DOI: 10.1158/1078-0432.Ccr-16-2353  0.352
2017 Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch BA, Kahwash SB, Choi J, Kolb EA, Gamis AS, Aplenc R. Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children’s Oncology Group report. Journal of Clinical Oncology. 35: 10515-10515. DOI: 10.1200/Jco.2017.35.15_Suppl.10515  0.434
2017 Horowitz JP, Fisher BT, Szymczack JE, Li Y, Mann JP, Galvelis T, Suarez R, Sack L, He C, Yver H, Stevens A, Arnold SD, Gramatges MMM, Winick N, Hijiya N, ... ... Aplenc R, et al. A Multicenter Comparison of Rates of Central Venous Catheter-Associated Bloodstream Infections By Central Venous Catheter Type Among Pediatric Patients Receiving Treatment for Newly Diagnosed Acute Myeloid Leukemia Blood. 130: 610-610. DOI: 10.1182/Blood.V130.Suppl_1.610.610  0.349
2017 Cooper TM, Ries RE, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Raimondi SC, Hirsch BA, Aplenc R, Gamis AS, Kolb EA, Meshinchi S. Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 130: 407-407. DOI: 10.1182/Blood.V130.Suppl_1.407.407  0.441
2017 Brodersen LE, Alonzo TA, Gerbing RB, Kolb A, Gamis AS, Aplenc R, Meshinchi S, Loken MR. Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031 Blood. 130: 3905-3905. DOI: 10.1182/Blood.V130.Suppl_1.3905.3905  0.336
2017 Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Barz A, Sack L, Woods WG, Alonzo TA, Gamis AS, Aplenc R. Occurrence of Cardiotoxicity and the Impact on Outcomes Among Children Treated on the AAML0531 Clinical Trial: A Report from the Children's Oncology Group Blood. 130: 3875-3875. DOI: 10.1182/Blood.V130.Suppl_1.3875.3875  0.433
2017 Maude SL, Hucks GE, Callahan C, Baniewicz D, Fasano C, Barker C, Rheingold SR, Aplenc R, Dinofia AM, Li A, Teachey DT, Barrett DM, Brogdon J, Young RM, Scholler J, et al. Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Blood. 130: 1319-1319. DOI: 10.1182/Blood.V130.Suppl_1.1319.1319  0.37
2017 Meyer JA, Mason CC, Maese L, Pei D, Cheng C, Pui C, Greaves M, Aplenc R, Mulligan CG, Raetz E, Miles RR, Rabin KR, Schiffman JD. Abstract 4884: Focal 22q11.22 deletions combined withIKZF1alterations are associated with worse clinical outcome in acute lymphoblastic leukemia Cancer Research. 77: 4884-4884. DOI: 10.1158/1538-7445.Am2017-4884  0.328
2017 Elgarten C, Arnold S, Li Y, Huang YV, Gerber JS, Saber W, Aplenc R, Fisher BT. Center-level variability in broad-spectrum antibiotic prescribing for children undergoing hematopoietic cell transplantion for acute leukemia. Open Forum Infectious Diseases. 4: S277-S278. DOI: 10.1093/Ofid/Ofx163.623  0.355
2017 Hucks G, Barrett D, Rheingold S, Aplenc R, Teachey D, Callahan C, Baniewicz D, White C, Talekar M, Shaw P, Brogdon J, Young R, Scholler J, Marcucci K, Chew A, et al. Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma Cytotherapy. 19: S9-S10. DOI: 10.1016/J.Jcyt.2017.02.011  0.329
2016 Winestone LE, Getz KD, Miller TP, Wilkes JJ, Sack L, Li Y, Huang YS, Seif AE, Bagatell R, Fisher BT, Epstein A, Aplenc R. The Role of Acuity of Illness at Presentation in Early Mortality in Black Children with Acute Myeloid Leukemia. American Journal of Hematology. PMID 27862214 DOI: 10.1002/Ajh.24605  0.383
2016 Vujkovic M, Aplenc R, Alonzo TA, Gamis AS, Li Y. Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. Frontiers in Genetics. 7: 139. PMID 27547214 DOI: 10.3389/Fgene.2016.00139  0.33
2016 Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Alonzo T, Gerbing R, Sung L, Hall M, Bagatell R, Gamis A, Fisher BT, Aplenc R. Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. Cancer Medicine. PMID 27474232 DOI: 10.1002/Cam4.839  0.408
2016 Lewen M, Gresh R, Queenan M, Paessler M, Pillai V, Hexner E, Frank D, Bagg A, Aplenc R, Caywood E, Wertheim G. Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report. Biomarker Research. 4: 14. PMID 27453784 DOI: 10.1186/S40364-016-0069-0  0.334
2016 Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang YC, Meshinchi S, Gamis AS. Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children's Oncology Group. International Journal of Cancer. PMID 27312107 DOI: 10.1002/Ijc.30236  0.43
2016 Wilkes JJ, Hennessy S, Xiao R, Rheingold S, Seif AE, Huang YS, Vendetti N, Li Y, Bagatell R, Aplenc R, Fisher BT. Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. Clinical Lymphoma, Myeloma & Leukemia. PMID 27246140 DOI: 10.1016/J.Clml.2016.04.016  0.336
2016 Salazar EG, Li Y, Fisher BT, Rheingold SR, Fitzgerald J, Seif AE, Huang YS, Bagatell R, Aplenc R. Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. British Journal of Haematology. PMID 27161549 DOI: 10.1111/Bjh.14085  0.379
2016 Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery. PMID 27076371 DOI: 10.1158/2159-8290.Cd-16-0040  0.334
2016 Heneghan MB, Rheingold SR, Li Y, Seif AE, Huang YS, McLeod L, Wells L, Fisher BT, Aplenc R. Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma & Leukemia. 16: 223-229.e2. PMID 27021949 DOI: 10.1016/J.Clml.2015.12.009  0.375
2016 DiNofia AM, Salazar E, Seif AE, Li Y, Huang YV, Bagatell R, Fisher BT, Aplenc R. Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. Plos One. 11: e0151362. PMID 26978062 DOI: 10.1371/Journal.Pone.0151362  0.353
2016 Sung L, Dix D, Cellot S, Gillmeister B, Ethier MC, Roslin NM, Johnston DL, Feusner J, Mitchell D, Lewis V, Aplenc R, Yanofsky R, Portwine C, Price V, Zelcer S, et al. Single nucleotide polymorphism in IL1B is associated with infection risk in pediatric acute myeloid leukemia. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. PMID 26932518 DOI: 10.1016/J.Cmi.2016.02.006  0.344
2016 Miller TP, Li Y, Kavcic M, Troxel AB, Huang YV, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, ... ... Aplenc R, et al. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26884558 DOI: 10.1200/Jco.2015.65.5860  0.331
2016 Desai AV, Seif AE, Li Y, Getz K, Fisher BT, Huang V, Mante A, Aplenc R, Bagatell R. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. Pediatric Blood & Cancer. PMID 26797923 DOI: 10.1002/Pbc.25893  0.344
2016 Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786921 DOI: 10.1200/Jco.2015.62.6846  0.337
2016 Miller TP, Getz KD, Kavcic M, Li Y, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, ... ... Aplenc R, et al. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leukemia & Lymphoma. 1-8. PMID 26727639 DOI: 10.3109/10428194.2015.1088652  0.422
2016 Maude SL, Teachey DT, Rheingold SR, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Frey NV, Nazimuddin F, Lacey SF, Zheng Z, Levine B, Melenhorst JJ, Motley L, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. Journal of Clinical Oncology. 34: 3011-3011. DOI: 10.1200/Jco.2016.34.15_Suppl.3011  0.359
2016 Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Shaw PA, Brogdon J, Young R, Scholler J, Marcucci K, Kulikovskaya I, Nazimuddin F, Zheng Z, Levine B, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. Journal of Clinical Oncology. 34: 3007-3007. DOI: 10.1200/Jco.2016.34.15_Suppl.3007  0.333
2016 Aplenc R, Meshinchi S, Sung L, Alonzo TA, Pollard J, Gerbing R, Raimondi SC, Hirsch BA, Loken MR, Winter L, Kahwash SB, Choi JK, Levine JE, Kolb EA, Gamis AS. The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group Blood. 128: 899-899. DOI: 10.1182/Blood.V128.22.899.899  0.459
2016 Ries RE, Bolouri H, Farrar JE, Lim EL, Triche TJ, Tarlock K, Auvil JG, Hirsch BA, Raimondi SC, Ma Y, Marra MA, Aplenc R, Guest EM, Kolb EA, Gamis AS, et al. Alteration of Chromatin Modifiers and Misregulation of Transcription Factors Define the Genomic Profile of Infant AML Blood. 128: 774-774. DOI: 10.1182/Blood.V128.22.774.774  0.336
2016 Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS. The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia - a Report from the Children's Oncology Group Blood. 128: 4016-4016. DOI: 10.1182/Blood.V128.22.4016.4016  0.364
2016 Arnold SD, Brazauskas R, He N, Li Y, Satwani P, Pulsipher MA, Hall M, Atsuta Y, Dalal JD, Hahn T, Bonfim C, Khera N, Aplenc R, Saber W. Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia Blood. 128: 3575-3575. DOI: 10.1182/Blood.V128.22.3575.3575  0.363
2016 Selim D, Alonzo TA, Othus M, Gerbing R, Ostronoff F, Tarlock K, Kutny MA, Aplenc R, Kolb EA, Radich JP, Appelbaum FR, Gamis AS, Stirewalt DL, Meshinchi S. Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration Blood. 128: 285-285. DOI: 10.1182/Blood.V128.22.285.285  0.375
2016 Tarlock K, Cooper TM, Alonzo TA, Gerbing R, Pollard J, Aplenc R, Kolb EA, Gamis AS, Meshinchi S. Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Blood. 128: 2846-2846. DOI: 10.1182/Blood.V128.22.2846.2846  0.3
2016 Cooper TM, Gerbing RB, Alonzo TA, Pollard J, Sung L, Kolb EA, Aplenc R, Meshinchi S, Gamis AS. Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group Blood. 128: 2794-2794. DOI: 10.1182/Blood.V128.22.2794.2794  0.432
2016 Sung L, Gerbing R, Alonzo TA, Wang Y, Orgel E, Gamis AS, Aplenc R. Excess Treatment-Related Mortality in Obese Children and Adolescents with Acute Myeloid Leukemia on AAML0531: A Report from the Children's Oncology Group Blood. 128: 2790-2790. DOI: 10.1182/Blood.V128.22.2790.2790  0.408
2016 Lamba JK, Chauhan L, Loken MR, Pollard J, Wang Y, Rhonda RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study Blood. 128: 2743-2743. DOI: 10.1182/Blood.V128.22.2743.2743  0.336
2016 Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Baniewicz D, White C, Talekar MK, Shaw PA, Brogdon JL, Young RM, Scholler J, Marcucci KT, Levine BL, et al. Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Blood. 128: 217-217. DOI: 10.1182/Blood.V128.22.217.217  0.359
2016 Guest EM, Hirsch BA, Kolb EA, Alonzo TA, Gerbing R, Aplenc R, Pollard J, Sung L, Meshinchi S, Gamis AS, Raimondi SC. Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531 Blood. 128: 1211-1211. DOI: 10.1182/Blood.V128.22.1211.1211  0.353
2016 Seif AE, Li Y, Aplenc R, Barrett DM, Casper JT, Freedman JL, Grupp SA, Margolis DA, Olson TS, Teachey DT, Wang Y, Talano JM, Bunin NJ. Favorable Chronic Graft-Versus-Host-Disease (GVHD), Event-Free (EFS), and Overall Survival (OS) Rates Following Partially CD3-Depleted Alternative Donor Peripheral Stem Cell Transplantation (PSCT) for Pediatric Hematologic Malignancies Biology of Blood and Marrow Transplantation. 22: S62-S63. DOI: 10.1016/J.Bbmt.2015.11.356  0.321
2015 Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A, Meshinchi S. Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26644412 DOI: 10.1182/Blood.V124.21.486.486  0.429
2015 Li Y, Hall M, Fisher BT, Seif AE, Huang YS, Bagatell R, Getz KD, Alonzo TA, Gerbing RB, Sung L, Adamson PC, Gamis A, Aplenc R. Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. Plos One. 10: e0143480. PMID 26606521 DOI: 10.1371/Journal.Pone.0143480  0.364
2015 Vujkovic M, Kershenbaum A, Wray L, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R. Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952. Leukemia Research Reports. 4: 47-50. PMID 26605150 DOI: 10.1016/J.Lrr.2015.05.005  0.34
2015 Lee GE, Fisher BT, Xiao R, Coffin SE, Feemster K, Seif AE, Bagatell R, Li Y, Huang YV, Aplenc R. Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society. 4: 290-296. PMID 26582867 DOI: 10.1093/Jpids/Piu066  0.318
2015 Dix D, Aplenc R, Bowes L, Cellot S, Ethier MC, Feusner J, Gillmeister B, Johnston DL, Lewis V, Michon B, Mitchell D, Portwine C, Price V, Silva M, Stobart K, et al. Impact of registration on clinical trials on infection risk in pediatric acute myeloid leukemia. International Journal of Cancer. Journal International Du Cancer. PMID 26515793 DOI: 10.1002/Ijc.29905  0.362
2015 Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26304895 DOI: 10.1200/Jco.2015.62.8289  0.411
2015 Freedman JL, Desai AV, Bailey LC, Aplenc R, Burnworth B, Zehentner BK, Teachey DT, Wertheim G. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. Pediatric Blood & Cancer. PMID 26274939 DOI: 10.1002/Pbc.25694  0.362
2015 Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. Cancer Genetics. 208: 408-13. PMID 26163103 DOI: 10.1016/J.Cancergen.2015.04.010  0.322
2015 Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, Heerema NA, Sung L, Aplenc R, Franklin J, Raimondi SC, Hirsch BA, Konkashbaev A, Cox NJ, Onel K, et al. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. Leukemia. PMID 26126966 DOI: 10.1038/Leu.2015.171  0.332
2015 Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Bagatell R, Fisher BT, Aplenc R. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Medicine. PMID 26105201 DOI: 10.1002/Cam4.481  0.414
2015 Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, ... Aplenc R, et al. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood & Cancer. PMID 25946708 DOI: 10.1002/Pbc.25569  0.347
2015 Johnston D, Gerbing R, Alonzo T, Aplenc R, Nagarajan R, Schulte F, Cullen P, Sung L. Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group. Plos One. 10: e0125290. PMID 25915772 DOI: 10.1371/Journal.Pone.0125290  0.38
2015 Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, ... Aplenc R, et al. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 62: 1184-9. PMID 25760019 DOI: 10.1002/Pbc.25475  0.388
2015 G Salazar E, Bernhardt MB, Li Y, Aplenc R, Adamson PC. The impact of chemotherapy shortages on COG and local clinical trials: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 62: 940-4. PMID 25704486 DOI: 10.1002/Pbc.25445  0.382
2015 Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K, Bagatell R, Fisher BT, Aplenc R. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatric Blood & Cancer. 62: 704-9. PMID 24668949 DOI: 10.1002/Pbc.25043  0.43
2015 Desai AV, Li Y, Heneghan M, Huang Y, Fisher B, Mante A, Grupp SA, Bunin NJ, Aplenc R, Bagatell R, Seif AE. Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB). Journal of Clinical Oncology. 33: e21009-e21009. DOI: 10.1200/Jco.2015.33.15_Suppl.E21009  0.378
2015 Miller TP, Li Y, Kavcic M, Alonzo TA, Hall M, Huang Y, Gerbing RB, Fisher B, Luger SM, Rubin D, Troxel AB, Sung L, Gamis AS, Aplenc R. Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 33: 10028-10028. DOI: 10.1200/Jco.2015.33.15_Suppl.10028  0.375
2015 Tolbert JA, Sung L, Aplenc R, Alonzo TA, Wang YJ, Gerbing RB, Meshinchi S, Gamis AS. Gemtuzumab ozogamycin (GO) and toxic mortality (TM) in children and adolescents with acute myeloid leukemia (AML) enrolled on Children’s Oncology Group (COG) trial AAML0531. Journal of Clinical Oncology. 33: 10008-10008. DOI: 10.1200/Jco.2015.33.15_Suppl.10008  0.438
2015 Pollard J, Alonzo TA, Gerbing RB, Wang Y, Joaquin J, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Bernstein ID, Gamis AS, Meshinchi S. Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 Blood. 126: 800-800. DOI: 10.1182/Blood.V126.23.800.800  0.368
2015 Pollard J, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Guest EM, Bernstein ID, Loken MR, Meshinchi S, Gamis AS. Treatment of 11q23/MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531 Blood. 126: 799-799. DOI: 10.1182/Blood.V126.23.799.799  0.451
2015 Maude SL, Barrett DM, Ambrose DE, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Barker CS, Mudambi M, Shaw PA, Brogdon J, Young RM, Scholler J, Loew A, Marcucci KT, et al. Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL Blood. 126: 683-683. DOI: 10.1182/Blood.V126.23.683.683  0.346
2015 Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Teachey DT, Wood PA, Porter D, June CH. Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) Blood. 126: 681-681. DOI: 10.1182/Blood.V126.23.681.681  0.363
2015 Tasian SK, Kenderian SS, Shen F, Li Y, Ruella M, Fix WC, Kozlowski M, Carroll M, Aplenc R, June CH, Grupp SA, Gill SI. Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity Blood. 126: 565-565. DOI: 10.1182/Blood.V126.23.565.565  0.312
2015 Winestone LE, Getz KD, Miller TP, Wilkes JJ, Sack L, Li Y, Huang Y, Seif AE, Bagatell R, Fisher BT, Epstein A, Aplenc R. Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction Blood. 126: 530-530. DOI: 10.1182/Blood.V126.23.530.530  0.359
2015 Satwani P, Brazauskas R, Arnold SD, He N, Li Y, Aplenc R, Hall M, Atsuta Y, Dalal JD, Hahn T, Jin Z, Sales-Bonfim C, Khera N, Saber W. A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation Blood. 126: 528-528. DOI: 10.1182/Blood.V126.23.528.528  0.439
2015 Keeshan B, Lin KY, O'Connor MJ, Ginsberg JP, Aplenc R, Shaddy R, Rossano J. Heart Failure Related Hospitalizations Are Associated with Increased Morbidity and Mortality in Pediatric Oncology Patients Blood. 126: 4482-4482. DOI: 10.1182/Blood.V126.23.4482.4482  0.327
2015 Rheingold SR, Chen LN, Maude SL, Aplenc R, Barker C, Barrett DM, Callahan C, Cebry K, Kulikovskaya I, Lacey SF, Levine BL, Melenhorst JJ, Shaw PA, Sparrow A, Teachey DT, et al. Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL Blood. 126: 3769-3769. DOI: 10.1182/Blood.V126.23.3769.3769  0.354
2015 Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Frey NV, Maude SL, Barrett DM, Aplenc R, Chen F, Fitzgerald J, Gonzalez V, Pequignot E, Rheingold SR, Weiss S, White JC, et al. Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Blood. 126: 1334-1334. DOI: 10.1182/Blood.V126.23.1334.1334  0.349
2015 Lamba JK, Chauhan L, Aplenc R, Skrypek M, Pollard J, Alonzo TA, Wang Y, Bernstein ID, Gamis AS, Meshinchi S. Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study Blood. 126: 1260-1260. DOI: 10.1182/Blood.V126.23.1260.1260  0.41
2014 Fisher BT, Sammons JS, Li Y, de Blank P, Seif AE, Huang YS, Kavcic M, Klieger S, Harris T, Torp K, Rheam D, Shah A, Aplenc R. Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society. 3: 329-335. PMID 26625453 DOI: 10.1093/Jpids/Piu008  0.325
2014 Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine. 371: 1507-17. PMID 25317870 DOI: 10.1056/Nejmoa1407222  0.4
2014 Goodman EK, Reilly AF, Fisher BT, Fitzgerald J, Li Y, Seif AE, Huang YS, Bagatell R, Aplenc R. Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals. Jama Pediatrics. 168: 925-31. PMID 25155012 DOI: 10.1001/Jamapediatrics.2014.1023  0.407
2014 Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3021-32. PMID 25092781 DOI: 10.1200/Jco.2014.55.3628  0.416
2014 Freedman JL, Faerber J, Kang TI, Dai D, Fisher BT, Huang YS, Li Y, Aplenc R, Feudtner C. Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatric Blood & Cancer. 61: 1798-805. PMID 24939039 DOI: 10.1002/Pbc.25108  0.418
2014 Wray L, Vujkovic M, McWilliams T, Cannon S, Devidas M, Stork L, Aplenc R. TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 61: 2086-8. PMID 24737678 DOI: 10.1002/Pbc.25057  0.382
2014 Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N, et al. Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. Blood. 123: 3504-11. PMID 24711663 DOI: 10.1182/Blood-2013-03-490334  0.382
2014 Tasian SK, Pollard JA, Aplenc R. Molecular therapeutic approaches for pediatric acute myeloid leukemia. Frontiers in Oncology. 4: 55. PMID 24672775 DOI: 10.3389/Fonc.2014.00055  0.404
2014 Desai AV, Kavcic M, Huang YS, Herbst N, Fisher BT, Seif AE, Li Y, Hennessy S, Aplenc R, Bagatell R. Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database. Pediatric Blood & Cancer. 61: 1129-31. PMID 24616331 DOI: 10.1002/Pbc.24930  0.337
2014 Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang YS, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, ... ... Aplenc R, et al. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 15: 112-20. PMID 24366507 DOI: 10.1097/Pcc.0000000000000042  0.401
2014 Fisher BT, Kavcic M, Li Y, Seif AE, Bagatell R, Huang YS, Zaoutis T, Torp K, Leckerman KH, Aplenc R. Antifungal prophylaxis associated with decreased induction mortality rates and resources utilized in children with new-onset acute myeloid leukemia. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: 502-8. PMID 24270167 DOI: 10.1093/Cid/Cit781  0.367
2014 Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YS, Harris T, Shah A, Hall M, Fieldston ES, Kavcic M, Vujkovic M, Bailey LC, Kersun LS, Reilly AF, ... ... Aplenc R, et al. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatric Blood & Cancer. 61: 846-52. PMID 24249480 DOI: 10.1002/Pbc.24855  0.343
2014 Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, Meshinchi S, Alonzo TA, Gamis A, Aplenc R. Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group. Acta Haematologica. 131: 167-9. PMID 24217778 DOI: 10.1159/000353758  0.351
2014 Fraser C, Brown P, Megason G, Ahn HS, Cho B, Kirov I, Frankel L, Aplenc R, Bensen-Kennedy D, Munteanu M, Weaver J, Harker-Murray P. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability. Journal of Pediatric Hematology/Oncology. 36: e212-8. PMID 24072240 DOI: 10.1097/Mph.0000000000000021  0.373
2014 Fisher BT, Singh S, Huang YS, Li Y, Gregory J, Walker D, Seif AE, Kavcic M, Aplenc R. Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatric Blood & Cancer. 61: 68-73. PMID 23868668 DOI: 10.1002/Pbc.24585  0.415
2014 Hagleitner MM, Coenen MJ, Aplenc R, Patiño-Garcia A, Chiusolo P, Gemmati D, De Mattei M, Ongaro A, Krajinovic M, Hoogerbrugge PM, Vermeulen SH, te Loo DM. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. The Pharmacogenomics Journal. 14: 115-9. PMID 23648444 DOI: 10.1038/Tpj.2013.19  0.339
2014 Fisher BT, Harris T, Torp K, Seif AE, Shah A, Huang YS, Bailey LC, Kersun LS, Reilly AF, Rheingold SR, Walker D, Li Y, Aplenc R. Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative data. Medical Care. 52: e1-6. PMID 22410405 DOI: 10.1097/Mlr.0B013E31824Deff9  0.391
2014 Wilkes JJ, Xiao R, Seif AE, Huang Y, Vendetti ND, Rheingold SR, Aplenc R, Hennessy S, Fisher B. Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume. Journal of Clinical Oncology. 32: e17703-e17703. DOI: 10.1200/Jco.2014.32.15_Suppl.E17703  0.359
2014 Aplenc R, Fisher B, Li Y, Alonzo TA, Gerbing RB, Hall M, Arnold SD, Huang Y, Seif AE, Bagatell R, Sung L, Adamson PC, Gamis AS, Keren R. Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children’s Oncology Group. Journal of Clinical Oncology. 32: 7086-7086. DOI: 10.1200/Jco.2014.32.15_Suppl.7086  0.383
2014 Goodman EK, Reilly AF, Li Y, Seif AE, Fitzgerald J, Huang Y, Bagatell R, Fisher B, Aplenc R. Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. children’s hospitals. Journal of Clinical Oncology. 32: 6598-6598. DOI: 10.1200/Jco.2014.32.15_Suppl.6598  0.353
2014 Bagatell R, Fisher B, Seif AE, Huang Y, Li Y, Desai AV, London WB, Van Ryn C, Park JR, Richardson T, Hall M, Aplenc R. Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data. Journal of Clinical Oncology. 32: 10069-10069. DOI: 10.1200/Jco.2014.32.15_Suppl.10069  0.367
2014 Goodman EK, Li Y, Seif AE, Fitzgerald J, Huang Y, Bagatell R, Fisher BT, Aplenc R. Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States Blood. 124: 553-553. DOI: 10.1182/Blood.V124.21.553.553  0.406
2014 Grupp SA, Maude SL, Shaw P, Aplenc R, Barrett DM, Callahan C, Chew A, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Shen A, Teachey DT, Wood PA, et al. T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL Blood. 124: 380-380. DOI: 10.1182/Blood.V124.21.380.380  0.366
2014 Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang Y, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531 Blood. 124: 377-377. DOI: 10.1182/Blood.V124.21.377.377  0.313
2014 Getz KD, Miller TP, Seif AE, Li Y, Huang Y, Bagatell R, Fisher BT, Aplenc R. Comparison of Resource Utilization in Children Discharged Versus Children That Remain Hospitalized Following Chemotherapy for Acute Myeloid Leukemia Blood. 124: 3697-3697. DOI: 10.1182/Blood.V124.21.3697.3697  0.392
2014 August KJ, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Horan JT, Alonzo TA, Gerbing RB, Wang YJ, Kahwash S, Heerema-McKenney A, Meshinchi S, Gamis AS. Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531 Blood. 124: 3672-3672. DOI: 10.1182/Blood.V124.21.3672.3672  0.435
2014 Ramamurthy R, Hughes MD, Bolouri H, Gerbing RB, Wang Y, Loken MR, Raimondi SC, Hirsch BA, Aplenc R, Gamis AS, Alonzo TA, Meshinchi S. Correlation of Mir-155 Expression with Clinical Outcome in Childhood AML: A Report from Children’s Oncology Group Blood. 124: 3545-3545. DOI: 10.1182/Blood.V124.21.3545.3545  0.352
2014 Johnston D, Rubnitz JE, Alonzo TA, Gerbing RB, Aplenc R, Gamis AS, Meshinchi S. An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Children’s Oncology Group Protocols AAML0531 and 03P1 and St Jude Children’s Research Hospital Protocol AML02 Blood. 124: 277-277. DOI: 10.1182/Blood.V124.21.277.277  0.422
2014 Wilkes JJ, Hennessy S, Xiao R, Rheingold SR, Seif AE, Huang Y, Vendetti N, Li Y, Bagatell R, Aplenc R, Fisher BT. Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL) Blood. 124: 2653-2653. DOI: 10.1182/Blood.V124.21.2653.2653  0.364
2014 Rao P, Li Y, Alonzo TA, Sung L, Gerbing RB, Getz KD, Seif AE, Miller TP, Huang Y, Bagatell R, Hall M, Fisher BT, Gamis AS, Aplenc R. Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children’s Oncology Group Blood. 124: 2286-2286. DOI: 10.1182/Blood.V124.21.2286.2286  0.407
2014 DiNofia AM, Seif AE, Devidas M, Li Y, Hall M, Huang YV, Bagatell R, Carroll WL, Winick NJ, Hunger SP, Fisher BT, Larsen EC, Aplenc R. ­Resource Utilization and Cost Analysis By Treatment Arm on the Children’s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children’s Oncology Group Blood. 124: 210-210. DOI: 10.1182/Blood.V124.21.210.210  0.361
2014 Schuback HL, Alonzo TA, Gerbing RB, Miller KL, Kahwash S, Heerema-Mckenney A, Hirsch BA, Raimondi SC, Aplenc R, Gamis AS, Meshinchi S. CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children’s Oncology Group Report Blood. 124: 13-13. DOI: 10.1182/Blood.V124.21.13.13  0.397
2014 Grupp SA, Maude S, Aplenc R, Barrett DM, Kalos M, Levine B, Lichtman M, Rheingold S, Shen A, Strait C, Teachey D, Wood PA, June C. Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr06  0.366
2013 Johnston DL, Nagarajan R, Caparas M, Schulte F, Cullen P, Aplenc R, Sung L. Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Plos One. 8: e74549. PMID 24040278 DOI: 10.1371/Journal.Pone.0074549  0.387
2013 Lothstein K, Fisher B, Li Y, Seif A, Harris T, Torp K, Kavcic M, Huang YS, Rheingold SR, Aplenc R. Zoonotic infections in pediatric patients with acute leukemia. Pediatric Blood & Cancer. 60: E160-2. PMID 23956002 DOI: 10.1002/Pbc.24596  0.403
2013 Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121: 5154-7. PMID 23678006 DOI: 10.1182/Blood-2013-02-485623  0.327
2013 Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England Journal of Medicine. 368: 1509-18. PMID 23527958 DOI: 10.1056/Nejmoa1215134  0.328
2013 de Blank P, Zaoutis T, Fisher B, Troxel A, Kim J, Aplenc R. Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. The Journal of Pediatrics. 163: 699-705.e1. PMID 23477996 DOI: 10.1016/J.Jpeds.2013.01.062  0.318
2013 Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood. 121: 3573-7. PMID 23471307 DOI: 10.1182/Blood-2013-01-476614  0.359
2013 Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Walker DM, Huang YS, Lee GE, Tasian SK, Vujkovic M, Bagatell R, Aplenc R. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer. 119: 1916-23. PMID 23436301 DOI: 10.1002/Cncr.27957  0.413
2013 Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatric Blood & Cancer. 60: 728-33. PMID 23303597 DOI: 10.1002/Pbc.24464  0.326
2013 Kavcic M, Fisher BT, Seif AE, Li Y, Huang YS, Walker D, Aplenc R. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. The Journal of Pediatrics. 162: 1252-8, 1258.e1. PMID 23269206 DOI: 10.1016/J.Jpeds.2012.11.038  0.341
2013 Kavcic M, Fisher BT, Torp K, Li Y, Huang YS, Seif AE, Vujkovic M, Aplenc R. Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database. Pediatric Blood & Cancer. 60: 508-11. PMID 23192853 DOI: 10.1002/Pbc.24402  0.406
2013 Fisher BT, Gerber JS, Leckerman KH, Seif AE, Huang YS, Li Y, Harris T, Torp K, Douglas R, Shah A, Walker D, Aplenc R. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leukemia & Lymphoma. 54: 1633-9. PMID 23163631 DOI: 10.3109/10428194.2012.750722  0.348
2013 Kang TI, Hexem K, Localio R, Aplenc R, Feudtner C. The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists. Pediatric Blood & Cancer. 60: 88-94. PMID 23024072 DOI: 10.1002/Pbc.24329  0.345
2013 Walker DM, Fisher BT, Seif AE, Huang YS, Torp K, Li Y, Aplenc R. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database. Pediatric Blood & Cancer. 60: 616-20. PMID 22948886 DOI: 10.1002/Pbc.24270  0.447
2013 Grupp SA, Porter DL, Levine B, Kalos M, Strait C, Rheingold SR, Aplenc R, June CH. Pilot study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRζ and 4-1BB signaling domains in patients with chemotherapy-resistant or -refractory CD19+ leukemia and lymphoma. Journal of Clinical Oncology. 31: TPS10072-TPS10072. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps10072  0.352
2013 Miller TP, Kavcic M, Li Y, Alonzo TA, Hall M, Huang Y, Gerbing RB, Fisher BT, Luger S, Rubin D, Troxel A, Sung L, Gamis AS, Aplenc R. Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group Blood. 122: 931-931. DOI: 10.1182/Blood.V122.21.931.931  0.417
2013 Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey DT, Wood PA, Porter D, et al. T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL Blood. 122: 67-67. DOI: 10.1182/Blood.V122.21.67.67  0.369
2013 Horan JT, Meshinchi S, Loken MR, Alonzo TA, Aplenc R, Davies SM, Gerbing RB, Gamis AS. Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission Blood. 122: 65-65. DOI: 10.1182/Blood.V122.21.65.65  0.429
2013 Alonzo TA, Gerbing RB, Kahwash S, Heerema-McKenney A, Aplenc R, Sung L, Winter L, Glick K, Ccrp, Davies SM, Byron P, Lavey RS, Smith FO, Ho PA, Gamis AS, et al. Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report Blood. 122: 612-612. DOI: 10.1182/Blood.V122.21.612.612  0.366
2013 Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Alonzo TA, Gerbing RB, Gamis AS, Meshinchi S, Aplenc R. Genomic Architecture and Treatment Response In Pediatric Acute Myeloid Leukemia: A Report From The Children’s Oncology Group Blood. 122: 610-610. DOI: 10.1182/Blood.V122.21.610.610  0.357
2013 Pollard J, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch B, Aplenc R, Gamis AS, Loken MR, Meshinchi S. Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group Blood. 122: 491-491. DOI: 10.1182/Blood.V122.21.491.491  0.361
2013 Aplenc R, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi SC, Hirsch B, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Ccrp, Davies SM, Byron P, Smith FO. Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531 Blood. 122: 355-355. DOI: 10.1182/Blood.V122.21.355.355  0.44
2013 Sung L, Aplenc R, Alonzo TA, Gerbing RB, Meshinchi S, Gamis AS. Duration Of Neutropenia Is Associated With Reduced Relapse Risk In Children With De Novo Acute Myeloid Leukemia: A Report From The Children’s Oncology Group Blood. 122: 2650-2650. DOI: 10.1182/Blood.V122.21.2650.2650  0.44
2013 Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch B, Kahwash S, Heerema-McKenney A, Gamis AS, Meshinchi S. Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group Blood. 122: 2609-2609. DOI: 10.1182/Blood.V122.21.2609.2609  0.344
2013 Heneghan MB, Rheingold SR, Li Y, Seif AE, Huang Y, Fisher BT, Aplenc R. Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS) Blood. 122: 1689-1689. DOI: 10.1182/Blood.V122.21.1689.1689  0.326
2012 Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 97: 1770-3. PMID 22801969 DOI: 10.3324/Haematol.2012.065490  0.384
2012 Aplenc R, Fisher BT, Huang YS, Li Y, Alonzo TA, Gerbing RB, Hall M, Bertoch D, Keren R, Seif AE, Sung L, Adamson PC, Gamis A. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiology and Drug Safety. 21: 37-43. PMID 22552978 DOI: 10.1002/Pds.3241  0.364
2012 Meshinchi S, Hunger SP, Aplenc R, Adamson PC, Jessup JM. Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1547-54. PMID 22422407 DOI: 10.1158/1078-0432.Ccr-11-2205  0.329
2012 Lehrnbecher T, Aplenc R, Rivas Pereira F, Lassaletta A, Caselli D, Kowalczyk J, Chisholm J, Sung L. Variations in non-pharmacological anti-infective measures in childhood leukemia--results of an international survey. Haematologica. 97: 1548-52. PMID 22419572 DOI: 10.3324/Haematol.2012.062885  0.302
2012 Christie JD, Wurfel MM, Feng R, O'Keefe GE, Bradfield J, Ware LB, Christiani DC, Calfee CS, Cohen MJ, Matthay M, Meyer NJ, Kim C, Li M, Akey J, Barnes KC, ... ... Aplenc R, et al. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. Plos One. 7: e28268. PMID 22295056 DOI: 10.1371/Journal.Pone.0028268  0.325
2012 Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M, Devidas M, Lange B, Rebbeck TR, Aplenc R. Germline genetic variation and treatment response on CCG-1891. Pediatric Blood & Cancer. 58: 695-700. PMID 21618417 DOI: 10.1182/Blood.V116.21.2711.2711  0.616
2012 Walker DM, Li Y, Huang Y, Seif AE, Kavcic M, Torp K, Fisher B, Aplenc R. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients. Journal of Clinical Oncology. 30: 1504-1504. DOI: 10.1200/Jco.2012.30.15_Suppl.1504  0.445
2012 Ostronoff F, Alonzo TA, Gerbing RB, Loken MR, Pardo L, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Lavey RS, et al. Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group Blood. 120: 529-529. DOI: 10.1182/Blood.V120.21.529.529  0.412
2012 Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Huang Y, Lee GE, Tasian SK, Desai AV, Vujkovic M, Bagatell R, Aplenc R. Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States Blood. 120: 4283-4283. DOI: 10.1182/Blood.V120.21.4283.4283  0.416
2012 Kavcic M, Fisher BT, Gerber JS, Leckerman KH, Li Y, Huang Y, Seif AE, Torp K, Bagatell R, Aplenc R. Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States Blood. 120: 4278-4278. DOI: 10.1182/Blood.V120.21.4278.4278  0.381
2012 Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of Supportive Care Measurements to Reduce Infections During Induction for Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group Blood. 120: 1478-1478. DOI: 10.1182/Blood.V120.21.1478.1478  0.379
2012 Ho PA, Alonzo TA, Gerbing RB, Sung L, Aplenc R, Pollard JA, Kuhn J, Heerema NA, Lange BJ, Gamis AS, Meshinchi S. WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group Blood. 120: 1385-1385. DOI: 10.1182/Blood.V120.21.1385.1385  0.399
2011 De Blank PM, Zaoutis T, Fisher B, Troxel AB, Kim J, Aplenc R. Risk factors for clostridium difficile infection in children with malignancy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9533. PMID 28019781 DOI: 10.1200/Jco.2011.29.15_Suppl.9533  0.344
2011 Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Adamson PC. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 839-44. PMID 21263099 DOI: 10.1200/Jco.2010.30.7231  0.32
2011 Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, DeMichele A. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Research : Bcr. 13: R8. PMID 21251330 DOI: 10.1186/Bcr2813  0.486
2011 Johnson KA, Aplenc R, Bagatell R. Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005. Pediatric Blood & Cancer. 56: 425-31. PMID 21072824 DOI: 10.1002/Pbc.22825  0.316
2011 Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, et al. Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531 Blood. 118: 939-939. DOI: 10.1182/Blood.V118.21.939.939  0.421
2011 Sepe D, Fisher BT, Seif AE, Huang YV, Li Y, Aplenc R. Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009 Blood. 118: 4242-4242. DOI: 10.1182/Blood.V118.21.4242.4242  0.461
2011 Fraser C, Brown PA, Megason GC, Ahn HS, Cho B, Kirov II, Frankel LS, Aplenc R, Bensen-Kennedy DM, Munteanu MC, Weaver J, Harker-Murray P. Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes, Blood. 118: 3602-3602. DOI: 10.1182/Blood.V118.21.3602.3602  0.412
2011 Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, et al. Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group, Blood. 118: 3545-3545. DOI: 10.1182/Blood.V118.21.3545.3545  0.429
2011 Aplenc R, Fisher BT, Sung L, Keren R, Alonzo TA, Hall M, Huang YV, Li Y, Luan X, Gerbing RB, Bertoch D, Seif AE, Adamson PC, Gamis AS. Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group Blood. 118: 2617-2617. DOI: 10.1182/Blood.V118.21.2617.2617  0.392
2010 Fisher BT, Zaoutis TE, Leckerman KH, Localio R, Aplenc R. Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. Pediatric Blood & Cancer. 55: 655-61. PMID 20533519 DOI: 10.1002/Pbc.22601  0.385
2010 Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Research : Bcr. 12: R26. PMID 20459744 DOI: 10.1186/Bcr2570  0.514
2010 Ginsberg JP, Aplenc R, McDonough J, Bethel J, Doyle J, Weiner DJ. Pre-transplant lung function is predictive of survival following pediatric bone marrow transplantation. Pediatric Blood & Cancer. 54: 454-60. PMID 19876892 DOI: 10.1002/Pbc.22337  0.302
2010 Johnson K, Aplenc R, Bagatell R. Survival by race among children with extracranial solid malignancies. Journal of Clinical Oncology. 28: 9559-9559. DOI: 10.1200/Jco.2010.28.15_Suppl.9559  0.393
2010 Seif AE, Rheingold SR, Fisher BT, Huang YV, Li Y, Kersun LS, Bailey LC, Reilly AF, Aplenc R. Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999–2009 Blood. 116: 3239-3239. DOI: 10.1182/Blood.V116.21.3239.3239  0.395
2010 Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, et al. Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531 Blood. 116: 2740-2740. DOI: 10.1182/Blood.V116.21.2740.2740  0.351
2010 Gamis AS, Alonzo TA, Gerbing RB, Aplenc R, Sung L, Meshinchi S, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, et al. Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531 Blood. 116: 182-182. DOI: 10.1182/Blood.V116.21.182.182  0.356
2010 Sung L, Alonzo TA, Gerbing RB, Aplenc R, Meshinchi S, Burden L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, et al. High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Blood. 116: 1072-1072. DOI: 10.1182/Blood.V116.21.1072.1072  0.4
2010 Sung L, Aplenc R, Alonzo TA, Gerbing RB, Meshinchi S, Burden L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, et al. Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group. Blood. 116: 1071-1071. DOI: 10.1182/Blood.V116.21.1071.1071  0.386
2009 Rajić V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leukemia & Lymphoma. 50: 1693-8. PMID 19863340 DOI: 10.1080/10428190903177212  0.302
2009 Fisher BT, Aplenc R, Localio R, Leckerman KH, Zaoutis TE. Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study. The Pediatric Infectious Disease Journal. 28: 971-5. PMID 19859014 DOI: 10.1097/Inf.0B013E3181A75939  0.386
2009 Lehrnbecher T, Ethier MC, Zaoutis T, Creutzig U, Gamis A, Reinhardt D, Aplenc R, Sung L. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. British Journal of Haematology. 147: 125-8. PMID 19663826 DOI: 10.1111/J.1365-2141.2009.07844.X  0.33
2009 DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS. Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Research. 69: 4184-91. PMID 19435922 DOI: 10.1158/0008-5472.Can-08-2989  0.376
2009 Reddy AJ, Christie JD, Aplenc R, Fuchs B, Lanken PN, Kleeberger SR. Association of human NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism with development of acute lung injury. Journal of Cellular and Molecular Medicine. 13: 1784-91. PMID 19017358 DOI: 10.1111/J.1582-4934.2008.00581.X  0.335
2009 Sung L, Alibhai SMH, Beyene J, Gamis A, Almeida R, Smith S, Aplenc R. Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: A meta-analysis of randomized trials Leukemia. 23: 811-813. PMID 18987652 DOI: 10.1038/Leu.2008.305  0.325
2009 Bunin N, Grupp S, Aplenc R, Brown V, Monos D, Pierson G. Altenative Donor Peripheral Stem Cell Transplant (PSCT) with CD3+ Depletion and CD3+ Addback for Pediatric Patients with Leukemias Biology of Blood and Marrow Transplantation. 15: 49. DOI: 10.1016/J.Bbmt.2008.12.151  0.301
2008 Bunin NJ, Davies SM, Aplenc R, Camitta BM, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4326-32. PMID 18779619 DOI: 10.1200/Jco.2008.16.4442  0.362
2008 Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, Feusner J, Franklin J, Patterson MJ, Gamis AS. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer. 51: 784-6. PMID 18680152 DOI: 10.1002/Pbc.21710  0.358
2008 Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, Bernstein I, Buckley P, Krimmel K, Smith FO, Sievers EL, Arceci RJ. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2390-3295. PMID 18467731 DOI: 10.1200/Jco.2007.13.0096  0.388
2008 Bulley S, Gassas A, Dupuis LL, Aplenc R, Beyene J, Greenberg ML, Doyle JJ, Sung L. Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation. British Journal of Haematology. 140: 214-7. PMID 18028482 DOI: 10.1111/J.1365-2141.2007.06900.X  0.365
2007 DeMichele A, Gimotty P, Botbyl J, Aplenc R, Colligon T, Foulkes AS, Rebbeck TR. In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 5675-7. PMID 18065748 DOI: 10.1200/Jco.2006.10.1485  0.45
2007 Cunningham L, Aplenc R. Pharmacogenetics of acute lymphoblastic leukemia treatment response. Expert Opinion On Pharmacotherapy. 8: 2519-31. PMID 17931087 DOI: 10.1517/14656566.8.15.2519  0.356
2007 Mehta PA, Eapen M, Klein JP, Gandham S, Elliott J, Zamzow T, Combs M, Aplenc R, MacMillan ML, Weisdorf DJ, Petersdorf E, Davies SM. Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. British Journal of Haematology. 137: 152-7. PMID 17391495 DOI: 10.1111/J.1365-2141.2007.06552.X  0.312
2007 Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 2237-46. PMID 17384144 DOI: 10.1096/Fj.06-7759Com  0.322
2007 Gor PP, Gray RJ, Horn M, Rebbeck TR, Gimotty PA, Aplenc R, Pins M, Tallman MS, DeMichele A. Association of polymorphic drug metabolizing enzymes (DME) with outcomes in breast cancer patients treated on the ECOG 2190/Intergroup 0121 (E2190/Int0121) study Journal of Clinical Oncology. 25: 596-596. DOI: 10.1200/Jco.2007.25.18_Suppl.596  0.55
2007 Adamson PC, Zhao H, Sievert A, Troxel A, Aplenc R. A simulation study to define the number of patients necessary to meet primary pharmacokinetic (pk) aims of phase I oncology trials Journal of Clinical Oncology. 25: 2579-2579. DOI: 10.1200/Jco.2007.25.18_Suppl.2579  0.483
2006 Aplenc R, Blanco J, Leisenring W, Davies S, Relling M, Robison L, Sklar C, Stovall M, Bhatia S. Polymorphisms in candidate genes in patients with congestive heart failure (CHF) after childhood cancer: A Report from the Childhood Cancer Survivor Study (CCSS). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 9004. PMID 27954251 DOI: 10.1200/Jco.2006.24.18_Suppl.9004  0.342
2006 Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood. 108: 74-80. PMID 16537811 DOI: 10.1182/Blood-2005-10-4004  0.379
2006 Bunin N, Aplenc R, Grupp S, Pierson G, Monos D. Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias Bone Marrow Transplantation. 37: 143-149. PMID 16284615 DOI: 10.1038/Sj.Bmt.1705211  0.361
2005 DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M, Foulkes A, Gimotty P, Glick J, Weber B, Stadtmauer E, Rebbeck TR. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5552-9. PMID 16110016 DOI: 10.1200/Jco.2005.06.208  0.517
2005 Jazbec J, Kitanovski L, Aplenc R, Debeljak M, Dolzan V. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia. Leukemia & Lymphoma. 46: 893-7. PMID 16019535 DOI: 10.1080/10428190500086428  0.391
2005 Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 106: 1183-8. PMID 15886328 DOI: 10.1182/Blood-2004-10-3821  0.397
2005 Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Research. 65: 2482-7. PMID 15781665 DOI: 10.1158/0008-5472.Can-04-2606  0.639
2005 Bunin N, Aplenc R, Iannone R, Leahey A, Grupp S, Monos D, Pierson G. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: Minimal GVHD and durable engraftment with partial T cell depletion Bone Marrow Transplantation. 35: 369-373. PMID 15640818 DOI: 10.1038/Sj.Bmt.1704803  0.398
2005 Bunin N, Aplenc R, Leahey A, Magira E, Grupp S, Pierson G, Monos D. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias Bone Marrow Transplantation. 35: 151-158. PMID 15531896 DOI: 10.1038/Sj.Bmt.1704754  0.396
2005 Aplenc R, Alonzo TA, Gerbing R, Smith FO, Eric S, Arceci RJ. Treatment of Children with Relapsed Acute Myeloid Leukemia with Gemtuzumab in Combination with Mitoxantrone and Cytarabine. Blood. 106: 4641-4641. DOI: 10.1182/Blood.V106.11.4641.4641  0.369
2005 Mehta PA, Eapen M, Gandham S, Elliott J, Combs M, Wilke T, Aplenc R, MacMillan ML, Weisdorf DJ, Petersdorf EW, Klein J, Davies SM. Interleukin-1 α Genotype and Outcome of Unrelated Donor BMT for CML. Blood. 106: 2057-2057. DOI: 10.1182/Blood.V106.11.2057.2057  0.331
2004 Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, Patacsil M, Aplenc R, Wein AJ, Malkowicz SB, Rebbeck TR. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Research. 64: 8461-7. PMID 15548719 DOI: 10.1158/0008-5472.Can-04-1651  0.536
2004 Aplenc R. Genetic polymorphisms of CYP1A1, CYP2D6, GSTM1, and GSTT1 and susceptibility to acute lymphoblastic leukemia in Indian children. Pediatric Blood & Cancer. 43: 539-41. PMID 15382269 DOI: 10.1002/Pbc.20167  0.347
2004 Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. British Journal of Haematology. 125: 421-34. PMID 15142113 DOI: 10.1111/J.1365-2141.2004.04932.X  0.374
2004 Powell JL, Bunin NJ, Callahan C, Aplenc R, Griffin G, Grupp SA. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34 + selected autologous peripheral blood stem cell transplant in neuroblastoma Bone Marrow Transplantation. 33: 651-657. PMID 14730339 DOI: 10.1038/Sj.Bmt.1704402  0.39
2004 Bunin N, Grupp S, Pierson G, Iannone R, Monos D, Aplenc R. Unrelated Donor (URD) or Partially Matched Related Donor (PMRD) Peripheral Stem Cell Transplant (PSCT) with CD34+ Selection and CD3+ Addback for Pediatric Patients with Leukemias. Blood. 104: 2159-2159. DOI: 10.1182/Blood.V104.11.2159.2159  0.359
2004 Rheingold SR, Bunin NJ, Aplenc R, Leahey AM, Lange BJ. Long Term Survival Using Intensive Multiagent Chemotherapy for Relapses of Pediatric Acute Lymphoblastic Leukemia (ALL). Blood. 104: 1953-1953. DOI: 10.1182/Blood.V104.11.1953.1953  0.366
2003 Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: A pediatric blood and marrow transplant consortium study Bone Marrow Transplantation. 32: 543-548. PMID 12953124 DOI: 10.1038/Sj.Bmt.1704198  0.426
2003 Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, Blackwood MA, Lange B, Rebbeck T. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. British Journal of Haematology. 122: 240-4. PMID 12846892 DOI: 10.1046/J.1365-2141.2003.04430.X  0.558
2003 Aplenc R, Zhao H, Rebbeck TR, Propert KJ. Group sequential methods and sample size savings in biomarker-disease association studies. Genetics. 163: 1215-9. PMID 12663557  0.528
2003 Grupp S, Powell J, Griffin G, Callahan C, Aplenc R, Bunin N. 11 High incidence of Epstein-Barr virus lymphoproliferative disease (EBV-LPD) after CD34-selected autologous peripheral blood stem cell transplant (PBSCT) in children with neuroblastoma(NB) Biology of Blood and Marrow Transplantation. 9: 66. DOI: 10.1016/S1083-8791(03)80012-5  0.318
2002 Aplenc R, Orudjev E, Swoyer J, Manke B, Rebbeck T. Differential bone marrow aspirate DNA yields from commercial extraction kits. Leukemia. 16: 1865-6. PMID 12200706 DOI: 10.1038/Sj.Leu.2402681  0.406
2001 Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 1688-97. PMID 11410508  0.385
2001 Langmuir PB, Aplenc R, Lange BJ. Acute myeloid leukaemia in children Best Practice and Research: Clinical Haematology. 14: 77-93. PMID 11355925 DOI: 10.1053/Beha.2000.0117  0.407
Show low-probability matches.